Aterian Q4 revenue $54.9M (-13.3% YoY), net loss $20.3M; reaffirms H2 2023 adj. EBITDA profitability target

Aterian, Inc.

Q4 2022 net revenue $54.9M, down 13.3% from $63.3M in Q4 2021.
Q4 gross margin fell to 37.1% from 45.6% due to liquidation of high-cost inventory.
Q4 adjusted EBITDA loss of $(16.2)M vs $(3.0)M in prior year.
Full year 2022 net loss $196.3M, including $120.4M goodwill impairment.
Q1 2023 revenue guidance $32-36M; reaffirms H2 2023 adj. EBITDA profitability.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Aterian, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue Fourth quarter 2022 net revenue declined 13.3% to $54.9 million, compared to $63.3 million in the fourth quarter of 2021, net income Fourth quarter 2022 net loss of $(20.3) million declined from $(6.6) million in 2021. Full year 2022 net loss of $(196.3. Guidance reaffirmed.

Period: fourth quarter and full year ended December 31, 2022
Revenue: Fourth quarter 2022 net revenue declined 13.3% to $54.9 million, compared to $63.3 million in the fourth quarter of 2021
Net income: Fourth quarter 2022 net loss of $(20.3) million declined from $(6.6) million in 2021. Full year 2022 net loss of $(196.3
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On March 9, 2023, Aterian, Inc. (the “Company”) issued a press release announcing its financial results for the year-ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Aterian, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-007086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.